Trulicity® is a GLP-1 receptor agonist indicated in adults with type 2 diabetes mellitus
Trulicity is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
as monotherapy when metformin is considered inappropriate due to intolerance or contraindications.
in addition to other medicinal products for the treatment of diabetes mellitus.
For study results with respect to combinations, effects on glycemic control and cardiovascular events, and the populations studied, see SPC sections 4.4, 4.5, and 5.1.
We have a Practical Guide that covers some key information that will support you in initiating your type 2 diabetes patient on Trulicity.
PP-DG-NO-0142 June 2021